OCRX Insider Trading Activity and SEC Form 4 Filings
OCRX insider trading summary
No open-market insider purchases or sales of Ocera Therapeutics, Inc. (OCRX) have been reported on SEC Form 4 in the past 12 months.
Latest OCRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 28, 2017 | Michael Byrnes | CFO and Treasurer | Buy | $4K (3,000 @ $1.28) |
| Dec 7, 2016 | Linda S Grais | President and CEO | Buy | $15K (7,000 @ $2.14) |
| Oct 13, 2016 | Stan Bukofzer | Chief Medical Officer | Buy | $7K (2,500 @ $2.64) |
| Sep 12, 2016 | Michael Powell | Director | Sell | $12K (5,372 @ $2.29) |
| Sep 12, 2016 | Michael Powell | Director | Sell | $170 (74 @ $2.29) |
| Sep 12, 2016 | Michael Powell | Director | Sell | $2K (1,066 @ $2.29) |
| Mar 4, 2016 | Linda S Grais | President and CEO | Buy | $10K (3,000 @ $3.19) |
| Jan 22, 2016 | Linda S Grais | President and CEO | Buy | $24K (10,000 @ $2.38) |
| Jan 15, 2016 | Gaurav Aggarwal | Chief Business Officer | Buy | $22K (10,000 @ $2.15) |
| Jan 15, 2016 | Michael Byrnes | CFO and Treasurer | Buy | $7K (3,500 @ $2.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.